AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05059223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken twice daily
Trial: NCT05353257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Q3W
Trial: NCT04971785
Drug: PTM SEMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as SC injection
Trial: NCT04971785
Drug: PTM CILO/FIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05566262
Drug: Bodewell Calming Cream
RxNorm normalized name: Eucerin Calming Itch Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
Trial: NCT06391853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.
Trial: NCT05578976
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05939414
Drug: AAA617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
Trial: NCT05781360
Drug: SIM0237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
Trial: NCT04972292
Drug: FDC of codeine 30 mg/dipyrone 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
Trial: NCT04972292
Drug: Tylex
RxNorm normalized name: Acetaminophen 325 MG Oral Tablet [TYLEX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
Trial: NCT06023862
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT06023862
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT05985850
Drug: Aurora 1:1 Drops (Indica)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
Trial: NCT05985850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
Trial: NCT05579730
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic Solution
Trial: NCT06596473
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Trial: NCT06620757
Drug: Single antiplatelet therapy (SAPT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
Trial: NCT06611111
Drug: Dextrose 5% (D5W)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorless liquid
Trial: NCT04777084
Drug: IBI318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
Trial: NCT06130553
Drug: AZD3470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.
Trial: NCT06473974
Drug: Test cosmetic product
RxNorm normalized name: Botox Cosmetic Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out.
Trial: NCT06387199
Drug: Placebo with 4 meal strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
Trial: NCT06508710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
Trial: NCT05546554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo given orally
Trial: NCT06226805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride for injection
Trial: NCT06141473
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for IV infusion
Trial: NCT06141473
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06141473
Drug: MRI contrast-enhancing agents
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, as per respective label
Trial: NCT06632444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06779370
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium hydroxide-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
Trial: NCT06368804
Drug: Antibiotic monotherapy treatment and follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Trial: NCT06368804
Drug: Antibiotic bitherapy treatment and follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Trial: NCT04564547
Drug: BIC/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC/FTC/TAF tablet taken by mouth.
Trial: NCT04564547
Drug: Placebo to ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to ISL taken by mouth.
Trial: NCT04564547
Drug: Placebo to BIC/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.
Trial: NCT06215144
Drug: NRCT-101SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRCT-101SR is a sustained release formulation.
Trial: NCT05807139
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information.
Trial: NCT05630833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT06796660
Drug: Nephropathy Formula No. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of integrated treatment for chronic kidney disease (the specific plan is the same as the control group), Nephropathy Formula No. 1 is given orally. The composition and decoction method of the formula are as follows: Bupleurum, Paeonia lactiflora Pall. , Scutellaria baicalensis Georgi , Pinellia ternata (Thunb.) Breit. , Smilax glabra Roxb. , Oldenlandia diffusa (Willd.) Roxb. , Tussilago farfara L. , Poria cocos (Schw.) Wolf , decocted into 300ml, one dose per day, taken warm in two divided doses for 12 weeks.
Trial: NCT06796660
Drug: integrated basic treatment for chronic kidney disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The integrated basic treatment for CKD includes the following:~Dietary Nutrition: α-Keto acid tablets (2.6 g tid) may be used. Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected. β-blockers or α-blockers may be used in combination if necessary.~Blood Sugar Control: Medications such as repaglinide tablets (1.0 mg qd) or gliclazide modified-release tablets (30 mg qd) can be used.~Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.~Anemia Treatment: Recombinant human erythropoietin (10000 u qw) can be administered via subcutaneous injection.~Regulation of Water, Electrolyte, and Acid-Base Metabolic Balance.
Trial: NCT06630091
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 by IV
Trial: NCT06630091
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 by IV
Trial: NCT04384367
Drug: Rizatriptan 10 mg + Naproxen 550mg
RxNorm normalized name: rizatriptan 10 MG
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral - single dose
Trial: NCT04384367
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral - single dose
Trial: NCT06162572
Drug: S095018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Trial: NCT06162572
Drug: S095024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Trial: NCT06162572
Drug: S095029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Trial: NCT06162572
Drug: S095018 Recommended Dose Expansion (RDE)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Trial: NCT06594939
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy drug, alkylating agent.
Trial: NCT06594939
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy drug, anthracycline antibiotic.
Trial: NCT06531018
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Trial: NCT05568095
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Tablets
Trial: NCT05568095
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Aqueous Solution
Trial: NCT05568095
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Aqueous Solution
Trial: NCT05835219
Drug: REBYOTA™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REBYOTA™ is administered in the rectum
Trial: NCT06425302
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06425302
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06034002
Drug: INCA033989
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCA033989 will be administered at protocol defined dose.
Trial: NCT06082037
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Depends on pharmaceutical presentation, Oral
Trial: NCT04912856
Drug: XEN496
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
Trial: NCT06338293
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin
Trial: NCT05686642
Drug: LT3001 Drug:low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion.
Trial: NCT04314219
Drug: Cyclophosphamide 50mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
Trial: NCT04314219
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
Trial: NCT05894239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
Trial: NCT05894239
Drug: Taxane-based Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
Trial: NCT05894239
Drug: Optional Endocrine Therapy of Investigator's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
Trial: NCT06345339
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Capsule
Trial: NCT05305664
Drug: Corresponding Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Pelacarsen
Trial: NCT06496490
Drug: TQB2102 for injection combined with Benmelstobart injection
RxNorm normalized name: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
Trial: NCT06355310
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take an identical appearing oral tablet with zero active ingredient.
Trial: NCT05531565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06459973
Drug: intravenous (IV) infusion
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
Trial: NCT05816694
Drug: Cisplatin plus Epirubicin plus Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
Trial: NCT06233331
Drug: Dose Level 1 ACU-D1 ointment
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks.
Trial: NCT06233331
Drug: Dose Level 2 ACU-D1 ointment
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
Trial: NCT06233331
Drug: Dose Level 3 ACU-D1 ointment
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
Trial: NCT06477536
Drug: HB0034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg, i.v. Q4W
Trial: NCT04233190
Drug: Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one inhalation, twice daily
Trial: NCT03868943
Drug: Soliramfetol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
Trial: NCT06564038
Drug: AZD0486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).
Trial: NCT06564038
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as IV infusion as per standard of care.
Trial: NCT06564038
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered as IV infusion as per standard of care.
Trial: NCT05936359
Drug: INCA033989
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCA033989 will be administered at protocol defined dose.
Trial: NCT05913752
Drug: CMND-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class